HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fish, K. J. Articles by Miller, D. C. Search for Related Content PubMed PubMed Citation Articles by Fish, K. J. Articles by Miller, D. C.

The Journal of Thoracic and Cardiovascular Surgery, Vol 91, 436-442, Copyright © 1986 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

A prospective, randomized study of the effects of prostacyclin on platelets and blood loss during coronary bypass operations

KJ Fish, FH Sarnquist, C van Steennis, RS Mitchell, M Hilberman, SW Jamieson, OI Linet and DC Miller

A randomized, double-blind study was designed to evaluate the therapeutic effect and safety of prostacyclin (epoprostenol) in patients undergoing cardiopulmonary bypass. One hundred patients having isolated coronary bypass grafting received 300 units/kg of heparin and then either prostacyclin (12.5 ng/kg/min from heparinization until cardiopulmonary bypass, 25 ng/kg/min during bypass) or buffer/diluent in a similar manner. Standardized anesthetic, perfusion, and surgical techniques were used. Drug and placebo groups were similar in demographic data and bypass times, and there were no deaths. Activated coagulation time and platelet count were significantly higher during cardiopulmonary bypass in patients receiving prostacyclin. Platelet count remained significantly higher 24 hours after bypass in the active drug group. Immediately after operation, there was significantly less prolongation of bleeding time (1.3 versus 2.9 minutes; p = 0.009) in the patients receiving prostacyclin. Blood loss was significantly reduced during the first 4 hours postoperatively in the prostacyclin group (261 +/- 159 versus 347 +/- 197 ml; p = 0.02). There was no significant difference between the groups when total blood loss was compared (710 +/- 351 versus 869 +/- 498 ml; p = 0.07). Patients receiving prostacyclin required an average of 257 ml less blood transfused in the intensive care unit (p = 0.02). We conclude that the clinical impact of prostacyclin in patients undergoing coronary artery operations was demonstrable, but small. Prostacyclin may provide clinical benefits in patients undergoing cardiopulmonary bypass when there are contraindications to or other difficulties with blood transfusion. With prostacyclin, reduced heparin dose is possible and therefore reduced protamine requirement would offer a potential benefit of less cardiovascular depression immediately after bypass. However, the advantages offered by prostacyclin are not sufficient to recommend its routine use during cardiopulmonary bypass.

This article has been cited by other articles:

				Y. Kadoi Pharmacological Neuroprotection During Cardiac Surgery Asian Cardiovasc Thorac Ann, April 1, 2007; 15(2): 167 - 177. [Abstract] [Full Text] [PDF]

				C. W. Hogue Jr, C. A. Palin, and J. E. Arrowsmith Cardiopulmonary bypass management and neurologic outcomes: an evidence-based appraisal of current practices. Anesth. Analg., July 1, 2006; 103(1): 21 - 37. [Abstract] [Full Text] [PDF]

				G. J. Despotis, M. S. Avidan, and C. W. Hogue Jr Mechanisms and attenuation of hemostatic activation during extracorporeal circulation Ann. Thorac. Surg., November 1, 2001; 72(5): S1821 - 1831. [Abstract] [Full Text] [PDF]

				S. C. Stamou, P. C. Hill, G. Dangas, A. J. Pfister, S. W. Boyce, M. K.C. Dullum, A. S. Bafi, P. J. Corso, and B. Silver Stroke After Coronary Artery Bypass : Incidence, Predictors, and Clinical Outcome Editorial Comment: Incidence, Predictors, and Clinical Outcome Stroke, July 1, 2001; 32(7): 1508 - 1513. [Abstract] [Full Text] [PDF]

				D. Royston Hemostatic Drugs in Prothrombotic or Hypercoagulable States Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 376 - 394. [Abstract] [PDF]

				D. Royston Systemic inflammatory responses to surgery with cardiopulmonary bypass Perfusion, May 1, 1996; 11(3): 177 - 189. [PDF]

				D. Katsaros, M. Petricevic, N. J. Snow, D. D. Woodhall, and R. Van Bergen Tranexamic Acid Reduces Postbypass Blood Use: A Double-Blinded, Prospective, Randomized Study of 210 Patients Ann. Thorac. Surg., April 1, 1996; 61(4): 1131 - 1135. [Abstract] [Full Text]

				J. H. Levy, R. Pifarre, H. V. Schaff, J. C. Horrow, R. Albus, B. Spiess, T. K. Rosengart, J. Murray, R. E. Clark, P. Smith, et al. A Multicenter, Double-Blind, Placebo-Controlled Trial of Aprotinin for Reducing Blood Loss and the Requirement for Donor-Blood Transfusion in Patients Undergoing Repeat Coronary Artery Bypass Grafting Circulation, October 15, 1995; 92(8): 2236 - 2244. [Abstract] [Full Text]

				J. I. Casas, I. Zuazu-Jausoro, J. Mateo, A. Oliver, H. Litvan, E. Muniz-Diaz, A. Aris, J. M. Caralps, and J. Fontcuberta APROTININ VERSUS DESMOPRESSIN FOR PATIENTS UNDERGOING OPERATIONS WITH CARDIOPULMONARY BYPASS: A double-blind placebo-controlled study J. Thorac. Cardiovasc. Surg., October 1, 1995; 110(4): 1107 - 1117. [Abstract] [Full Text]

				H. P. Wendel, W. Heller, J. Michel, G. Mayer, C. Ochsenfahrt, U. Graeter, J. Schulze, H.-M. Hoffmeister, and H.-E. Hoffmeister Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage J. Thorac. Cardiovasc. Surg., June 1, 1995; 109(6): 1164 - 1172. [Abstract] [Full Text]

				R. D Weisel Agents that modify haemostasis after cardiopulmonary bypass Perfusion, May 1, 1993; 8(1_suppl): 6 - 12. [Abstract] [PDF]

				C. Prentice, M. Orchard, and C. Goodchild Haemostatic dysfunction and cardiopulmonary bypass: mechanisms and therapeutic choices Perfusion, May 1, 1993; 8(1_suppl): 28 - 35. [Abstract] [PDF]

				D. Royston Aprotinin in open-heart surgery: background and results in patients having aortocoronary bypass grafts Perfusion, January 1, 1990; 5(1_suppl): 63 - 72. [PDF]

				B. P Bidstrup Review article : Blood conservation in cardiac surgery: can drugs help? Perfusion, July 1, 1988; 3(3): 171 - 177. [PDF]

				T. Spyt, D. Wheatley, I. Walker, J. Davidson, K. MacArthur, and W. Martin Placebo-controlled study of Iloprost (ZK 36374) in cardiopulmonary bypass surgery Perfusion, July 1, 1988; 3(3): 179 - 186. [Abstract] [PDF]